Outcome Measures: |
Primary: To evaluate the safety and tolerability of TT223 as a treatment for Type 2 diabetes at 1 mg, 2 mg and 3 mg., For the duration of the trial. | Secondary: To evaluate the efficacy of TT223 as a treatment for Type 2 diabetes by comparing the change in HbA1c value from baseline between the TT223 and placebo groups., For the duration of the trial.|To evaluate the efficacy of TT223 on beta cell function by assessing additional outcome measures including fasting blood glucose levels, and meal tolerance testing., For the duration of the trial.|To determine the pharmacokinetic (PK) parameter profile of TT223 in a subset of patients., Day 1 and Week 12 of treatment.
|
Locations: |
Artesia, California, United States|Los Angeles, California, United States|Santa Ana, California, United States|Torrence, California, United States|Walnut Creek, California, United States|Deland, Florida, United States|Bloomingdale, Illinois, United States|Grand Rapids, Michigan, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Clifton, New Jersey, United States|Asheboro, North Carolina, United States|Wilmington, North Carolina, United States|Bensalem, Pennsylvania, United States|Athens, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Richmond, Texas, United States|San Antonio, Texas, United States
|